Clinical trial • Phase I • Oncology
Autologous adult salivary gland stem cells for Head and neck cancer
Phase I trial of Autologous adult salivary gland stem cells for Head and neck cancer. 18 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Head and neck cancer
- Trial Stage
- Phase I
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 10-10-2024
- First CTIS Authorization Date
- 30-10-2024
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 18
Recruitment
- Planned Sample Size
- 18
- Recruitment Window Months
- 92
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 18
Netherlands
- Earliest CTIS Part Ii Submission Date
- 19-03-2024
- Latest Decision Or Authorization Date
- 30-10-2024
- Processing Time Days
- 225
- Number Of Sites
- 1
- Number Of Participants
- 18
Sites
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Radiation Oncology
- Principal Investigator Name
- R.J.H.M. Steenbakkers
- Principal Investigator Email
- r.steenbakkers@umcg.nl
- Contact Person Name
- R.J.H.M. Steenbakkers
- Contact Person Email
- r.steenbakkers@umcg.nl
- Number Of Participants
- 18
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Groningen
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- Autologous transplantation of adult salivary gland stem cells
- Active Substance
- Autologous adult salivary gland stem cells
- Modality
- Cell therapy
Related trials
Other published trials that may interest you.
- ROPIVACAINE for Head and neck cancer
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer